A retrospective multicentre study investigated patients with advanced BCC treated with HHI for factors linked to recurrence after CR [1]. Between 2016 and 2024, Dr Maria Mannino (Catholic University of the Sacred Heart, Italy) and colleagues included 106 adult patients who had received HHIs sonidegib (88.7%) or vismodegib (11.3%). The cohort’s mean age was 78 years, 35.8% were women and the median duration of HHI therapy was 18 months. Complete remission (CR) was achieved after a median of 8 months.
A BCC relapse after CR happened in 13.2% of the participants at a median of 12 months. High-risk histological subtypes (e.g. morpheiform, basosquamous, infiltrative, and micronodular) were more prevalent in the tumour recurrence arm (71.4%) versus the non-relapsing participants (28.3%). Consistent with this, further analyses identified having a low-risk subtype in the histology of BCC linked to a better chance of relapse-free survival with an odds ratio (OR) of 0.15 (95% CI 0.04–0.51; P=0.003) compared with a high-risk histology.
In addition, time to CR significantly influenced the risk of relapse (OR 1.07; 95% CI 1.01–1.15; P=0.04. Specifically, reaching CR in 8 months or less entailed a significantly higher probability of relapse-free survival (HR 0.14; 95% CI 0.047–0.43; P=0.0003).
All in all, this study identified histological risk features and time to CR as possible predictors of tumour recurrence after CR in advanced BCC. These findings may influence treatment decisions and follow-up strategies for patients with advanced BBC, receiving HHI therapy.
- Mannino M. Advanced basal cell carcinoma: clinical and histological predictors of tumor recurrence after complete response on hedgehog inhibitors. EPS02.02, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support provided by Karin Drooff, MPH
Posted on
Previous Article
« New targets identified for chronic wound healing Next Article
Semaglutide: also beneficial for patients with HS? »
« New targets identified for chronic wound healing Next Article
Semaglutide: also beneficial for patients with HS? »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
April 19, 2019
Novel anti-IgE drug enables durable urticaria control
November 18, 2021
Grand debate: Is psoriasis a systemic or skin-only disease?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com